 |
市场调查报告书
商品编码
1672700
小分子药物研发市场：依治疗领域、流程、最终用户和地区划分Small Molecule Drug Discovery Market, By Therapeutic Area, By Process, By End User, By Geography |
||||||
2025 年全球小分子药物研发市场规模预估为 610.4 亿美元，预计到 2032 年将达到 1,102.3 亿美元，2025 年至 2032 年的年复合成长率（CAGR）为 8.8%。
| 报告范围 | 报告详细信息 | ||
|---|---|---|---|
| 基准年 | [2024年] | 2025 年市场规模 | 610.4亿美元 |
| 效能资料 | 2020-2024 | 预测期 | 2025-2032 |
| 预测期：2025 年至 2032 年复合年增长率 | 8.80％ | 2032 年金额预测 | 1102.3亿美元 |
小分子药物具有大分子药物所不具备的优势，例如生物有效性度高、组织渗透性高。它也可以透过多种途径给药，包括口服和静脉注射。製药和生物技术公司对研发活动的投资不断增加以及对学名药的需求不断增长，推动了市场的成长。然而，临床试验期间的高退出率可能会阻碍市场的成长。此外，一些新兴企业正在利用人工智慧和机器学习等技术来加强药物发现过程并降低失败率。
市场动态
全球小分子药物研发市场的成长得益于医药研发支出的增加、学名药需求的不断增长以及合约研究和製造服务行业的增长。然而，候选药物的高临床失败率和严格的法规可能会阻碍市场的成长。人工智慧和机器学习在药物开发领域的开创性发展正在为市场参与企业创造新的机会。製药公司越来越多地采用此类技术来加快发现过程并优化分子设计。这可以减少离职率。目前，北美由于大型公司的存在和高额的医疗保健支出而占据市场主导地位。预计亚太地区将在不久的将来成为成长最快的市场。
研究的主要特点
本报告对全球小分子药物研发市场进行了详细分析，并以 2024 年为基准年，给出了预测期（2025-2032 年）的市场规模（十亿美元）和年复合成长率（CAGR%）。
它强调了各个领域的潜在商机并解释了该市场的有吸引力的投资提案矩阵。
它还提供了关于市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景以及主要企业采用的竞争策略的主要考察。
全球小分子药物研发市场的主要企业是根据公司亮点、产品系列、关键亮点、财务表现和策略等参数进行的分析。
主要企业包括辉瑞、百时美施贵宝、默克、安捷伦科技、Astra Zeneca、勃林格殷格翰和 Charles River Laboratories。
本报告的见解将使负责人和企业经营团队能够就未来产品发布、新兴趋势、市场扩张和行销策略做出明智的决策。
全球小分子药物发现市场报告针对该行业的各个相关人员，包括投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
相关人员将透过全球小分子药物发现市场分析中使用的各种策略矩阵来做出决策。
目录
第一章 调查目的与前提条件
- 研究目标
- 先决条件
- 简称
第二章 市场展望
- 报告描述
- 市场定义和范围
- 执行摘要
第三章市场动态、法规与趋势分析
- 市场动态
- 影响分析
- 监管情景
- 产品发布/核准
- PEST分析
- 波特分析
- 併购情景
4. 2020 年至 2032 年按治疗领域分類的全球小分子药物发现市场（美元）
- 介绍
- 肿瘤学
- 中枢神经系统
- 心血管
- 呼吸系统
- 代谢紊乱
- 胃肠道
- 其他的
5. 2020 年至 2032 年全球小分子药物发现市场（按流程划分）（美元）
- 介绍
- 目标识别/检验
- 命中生成和选择
- 线索识别
- 先导药物最适化
6. 2020 年至 2032 年全球小分子药物发现市场（以最终用户划分）（美元）
- 介绍
- 製药公司
- 生技公司
- 合约研究组织 (CRO)
- 学术研究所
- 其他的
7. 2020 年至 2032 年全球小分子药物发现市场（按地区划分）（美元）
- 介绍
- 北美洲
- 拉丁美洲
- 欧洲
- 亚太地区
- 中东
- 非洲
第八章 竞争格局
- Pfizer Inc.
- Merck & Co., Inc.
- Novartis AG
- Johnson & Johnson
- AstraZeneca PLC
- GlaxoSmithKline plc
- Bristol Myers Squibb
- Eli Lilly and Company
- Gilead Sciences, Inc.
- Teva Pharmaceuticals
- Boehringer Ingelheim GmbH
- Thermo Fisher Scientific Inc.
- Charles River Laboratories
- Labcorp Drug Development
- Agilent Technologies Inc.
- ICON Plc
- Eurofins Discovery
- Immunocure Inc.
- Acacia Pharma Group
- 4SC AG
第九章分析师建议
- 兴衰
- 一致的机会地图
第十章参考文献与调查方法
- 参考
- 调查方法
- 关于出版商
Global Small Molecule Drug Discovery Market is estimated to be valued at USD 61.04 Bn in 2025 and is expected to reach USD 110.23 Bn by 2032, growing at a compound annual growth rate (CAGR) of 8.8% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 61.04 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 8.80% | 2032 Value Projection: | USD 110.23 Bn |
Small molecule drugs have advantages over large molecule drugs such as higher oral bioavailability and better tissue penetration. These can be administered via various routes including oral, intravenous and others. Growing investment in R&D activities by pharmaceutical and biotech companies coupled with rising demand for generics can drive the market growth. However, high attrition rates during clinical trials can hamper the market growth. Several startups also leverage technologies such as artificial intelligence and machine learning to enhance the drug discovery process and reduce failure rates.
Market Dynamics:
Global small molecule drug discovery market growth is driven by rising pharmaceutical R&D spending, increasing demand for generic drugs, and growth of contract research and manufacturing services industries. However, high clinical failure rates of drug candidates and stringent regulations can hamper the market growth. Growing application of AI and machine learning in drug development offers new opportunities for the market players. Pharma companies are increasingly adopting such technologies to speed up the discovery process and optimize molecular designs. This can lower attrition rates. North America dominates the market currently, owing to presence of major players and high healthcare expenditure. Asia Pacific is anticipated to emerge as the fastest growing market in the near future.
Key features of the study:
This report provides in-depth analysis of the global small molecule drug discovery market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global small molecule drug discovery market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Pfizer, Bristol-Myers Squibb Company, Merck, Agilent Technologies, AstraZeneca, Boehringer Ingelheim, Charles River Laboratories
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global small molecule drug discovery market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global small molecule drug discovery market
Detailed Segmentation-
- Therapeutic Area Insights (Revenue, USD, 2020 - 2032)
- Oncology
- Central Nervous System
- Cardiovascular
- Respiratory
- Metabolic Disorders
- Gastrointestinal
- Others
- Process Insights (Revenue, USD, 2020 - 2032)
- Target ID/Validation
- Hit Generation and Selection
- Lead Identification
- Lead Optimization
- End User Insights (Revenue, USD, 2020 - 2032)
- Pharmaceutical Companies
- Biotechnology Companies
- Contract Research Organizations (CROs)
- Academic and Research Institutes
- Others
- Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Pfizer Inc.
- Merck & Co., Inc.
- Novartis AG
- Johnson & Johnson
- AstraZeneca PLC
- GlaxoSmithKline plc
- Bristol Myers Squibb
- Eli Lilly and Company
- Gilead Sciences, Inc.
- Teva Pharmaceuticals
- Boehringer Ingelheim GmbH
- Thermo Fisher Scientific Inc.
- Charles River Laboratories
- Labcorp Drug Development
- Agilent Technologies Inc.
- ICON Plc
- Eurofins Discovery
- Immunocure Inc.
- Acacia Pharma Group
- 4SC AG
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Small Molecule Drug Discovery Market, By Therapeutic Area
- Global Small Molecule Drug Discovery Market, By Process
- Global Small Molecule Drug Discovery Market, By End User
- Global Small Molecule Drug Discovery Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Global Small Molecule Drug Discovery Market, By Therapeutic Area, 2020-2032, (USD)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021- 2032
- Segment Trends
- Oncology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD)
- Central Nervous System
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD)
- Cardiovascular
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD)
- Respiratory
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD)
- Metabolic Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD)
- Gastrointestinal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD)
5. Global Small Molecule Drug Discovery Market, By Process, 2020-2032, (USD)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Target ID/Validation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD)
- Hit Generation and Selection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD)
- Lead Identification
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD)
- Lead Optimization
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD)
6. Global Small Molecule Drug Discovery Market, By End User, 2020-2032, (USD)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Pharmaceutical Companies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD)
- Biotechnology Companies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD)
- Contract Research Organizations (CROs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD)
- Academic and Research Institutes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD)
7. Global Small Molecule Drug Discovery Market, By Region, 2020 - 2032, (USD)
- Introduction
- Market Share (%) Analysis, 2025,2028 & 2032, (USD)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, (USD)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Therapeutic Area, 2020 - 2032, (USD)
- Market Size and Forecast, By Process, 2020 - 2032, (USD)
- Market Size and Forecast, By End User, 2020 - 2032, (USD)
- Market Size and Forecast, By Country, 2020 - 2032, (USD)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Therapeutic Area, 2020 - 2032, (USD)
- Market Size and Forecast, By Process, 2020 - 2032, (USD)
- Market Size and Forecast, By End User, 2020 - 2032, (USD)
- Market Size and Forecast, By Country, 2020 - 2032, (USD)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Therapeutic Area, 2020 - 2032, (USD)
- Market Size and Forecast, By Process, 2020 - 2032, (USD)
- Market Size and Forecast, By End User, 2020 - 2032, (USD)
- Market Size and Forecast, By Country, 2020 - 2032, (USD)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Therapeutic Area, 2020 - 2032, (USD)
- Market Size and Forecast, By Process, 2020 - 2032, (USD)
- Market Size and Forecast, By End User, 2020 - 2032, (USD)
- Market Size and Forecast, By Country, 2020 - 2032, (USD)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Therapeutic Area, 2020 - 2032, (USD)
- Market Size and Forecast, By Process, 2020 - 2032, (USD)
- Market Size and Forecast, By End User, 2020 - 2032, (USD)
- Market Size and Forecast, By Country, 2020 - 2032, (USD)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Therapeutic Area, 2020 - 2032, (USD)
- Market Size and Forecast, By Process, 2020 - 2032, (USD)
- Market Size and Forecast, By End User, 2020 - 2032, (USD)
- Market Size and Forecast, By Country/Sub-region, 2020 - 2032, (USD)
- South Africa
- North Africa
- Central Africa
8. Competitive Landscape
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca PLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GlaxoSmithKline plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bristol Myers Squibb
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Gilead Sciences, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Boehringer Ingelheim GmbH
- Thermo Fisher Scientific Inc.
- Charles River Laboratories
- Labcorp Drug Development
- Agilent Technologies Inc.
- ICON Plc
- Eurofins Discovery
- Immunocure Inc.
- Acacia Pharma Group
- 4SC AG
9. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
10. References and Research Methodology
- References
- Research Methodology
- About us
